Results 41 to 50 of about 78,921 (263)

In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. [PDF]

open access: yesPLoS ONE, 2018
Recent WHO guidelines recommend dual therapy with ceftriaxone or cefixime plus azithromycin for gonorrhea. Azithromycin in combination with gentamicin or spectinomycin has been recommended in treatment failure cases.
Vikram Singh   +4 more
doaj   +1 more source

Impact of prophylactic oral azithromycin during labor on Azithromycin Resistance (AMR) in nasal Staphylococcus aureus and Streptococcus pneumoniae in women and infants in the multi-country Azithromycin Prevention in Labor Use Study (A-PLUS).

open access: yesPLoS ONE
BackgroundProphylactic oral azithromycin vs. placebo reduced maternal, but not neonatal, mortality/sepsis in the A-PLUS Randomized Trial. While prophylactic intrapartum azithromycin reduces maternal mortality/sepsis, it may promote antimicrobial ...
Patricia L Hibberd   +30 more
doaj   +1 more source

Creation of an assessment system for measuring the bitterness of azithromycin-containing reverse micelles

open access: yesAsian Journal of Pharmaceutical Sciences, 2018
We aimed to develop a novel method for assessing the bitterness of azithromycin-containing reverse micelles (AM-containing RMs). Azithromycin-containing reverse micelles were prepared by processing Lipoid E80 and medium chain triglycerides via a freeze ...
Ri Huang   +6 more
doaj   +1 more source

Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. [PDF]

open access: yes, 2015
BACKGROUND: Mass drug administration (MDA) treatment of active trachoma with antibiotic is recommended to be initiated in any district where the prevalence of trachoma inflammation, follicular (TF) is ≥ 10% in children aged 1-9 years, and then to ...
Jaskiran K. Dhanjal   +73 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Nanomotion technology for testing azithromycin susceptibility of Salmonella enterica

open access: yesMicrobiology Spectrum
Invasive salmonellosis caused by Salmonella enterica subspecies affects millions of people every year, mostly children from low-income countries, and is associated with a high mortality rate. Azithromycin is used to treat invasive salmonellosis resistant
Mariliis Hinnu   +9 more
doaj   +1 more source

Advanced nanotherapeutics for combating ocular infections: Rational design, antimicrobial mechanisms, and therapeutic breakthroughs

open access: yesBMEMat, EarlyView.
Nanomaterials revolutionize ocular infection treatment by enabling targeted drug delivery and enhanced antimicrobial efficacy against resistant pathogens. This review systematically explores their rational design, multimodal mechanisms, and translational potential for next‐generation anti‐infective therapies.
Yujia Liu   +7 more
wiley   +1 more source

Azithromycin Prevents Pregnancy Loss: Reducing the Level of Tumor Necrosis Factor-Alpha and Raising the Level of Interleukin-10 in Rats

open access: yesMediators of Inflammation, 2013
The aim of this study was to determine the effect of azithromycin on LPS-induced pregnancy loss. Thirty-six pregnant female Wistar rats were divided into 4 equal groups as follows: control group, where 0.3 mL of normal saline solution was administered ...
Ayse Er
doaj   +1 more source

Long-term Azithromycin in Children With Bronchiectasis Unrelated to Cystic Fibrosis

open access: yes, 2023
Background: Following evidence from randomized controlled trials, patients with bronchiectasis unrelated to cystic fibrosis receive long-term azithromycin to reduce acute respiratory exacerbations.
Yerkovich, S   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy